Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.
Sign up now!
This section examines the current use of antiplatelet therapy/ASA for stroke prevention in patients with AF, and discusses the most recent guideline recommendations
Although the use of antiplatelet therapy (including ASA, aspirin) for stroke prevention in patients with AF is increasingly limited, patients with AF are still treated with antiplatelets without an indication for therapy:1
Recent guidelines have highlighted the limited risk–benefit of antiplatelet therapy for stroke prevention based on the efficacy profile and potential for causing serious bleeding events: